Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarco-mas have not yet been clearly defined. Although car-cinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive fac-tors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcino-sarcomas may benefit more from adjuvant CT.Aims: We aimed to define the prognostic and predic-tive factors associated with treatment options in ovar-ian (OCS) and uterine carcinosarcoma (UCS).Study Design: Retrospective cross-sectional studyMethods: We retrospectively reviewed the medical re-cords of patients with ovarian and uterine carcinosar-coma from 2000 to 2013, and 127 women were includ-ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey be-tween 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data ob-tained from well-kept medical records were included in this study. Stage IV tumours were excluded. The pa-tient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.Results: Age (>=70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dis-section did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p

PDF

___

Soslow RA. Mixed Müllerian tumors of the female genital tract. Surg Pathol Clin 2009;2:707-30. [CrossRef]
Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, et al. Uterine and ovary carcinosarcomas: outco- me, prognosis factors, and adjuvant therapy. Am J Clin Oncol 2015;38:272-7. [CrossRef]
Ariyoshi K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic factors in ovarian carcinosarcoma: a clinicopatholo- gical and immunohistochemical analysis of 23 cases. Histopat- hology 2000;37:427-36 [CrossRef]
del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol 2012;125:271-7. [CrossRef]
Kernochan LE, Garcia RL. Carcinosarcomas (malignant mi- xed Mullerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009;7:550-6; quiz 7.
Erickson BK, Doo DW, Zhang B, Huh WK, Leath CA 3rd. Black race independently predicts worse survival in uterine car- cinosarcoma. Gynecol Oncol 2014;133:238-41. [CrossRef]
Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002;12:348-53. [CrossRef]
Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 131:46-51. [CrossRef]
Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Can- cer 2010;20:888-94. [CrossRef]
Athavale R, Thomakos N, Godfrey K, Kew F, Cross P, de Barros Lopes A, et al. The effect of epithelial and stromal tumor compo- nents on FIGO stage III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy. Int J Gynecol Cancer 2007;17:1025-30. [CrossRef]
George E, Lillemoe TJ, Twiggs LB, Perrone T. Malignant mi- xed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a compara- tive analysis of survival. Int J Gynecol Pathol 1995;14:39-44. [CrossRef]
Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wil- kinson EJ, et al. Primary ovarian sarcoma: analysis of prog- nostic variables and the role of surgical cytoreduction. Cancer 1998;82:1731-7. [CrossRef]
Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the ovary: incidence, prognosis, treat- ment and survival of patients. Ann Oncol 1995;6:755-8.
Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. A clinical and pathologic study of 30 cases of malig- nant mixed mullerian epithelial and mesenchymal ovarian tu- mors: a Gynecologic Oncology Group study. Gynecol Oncol 1984;18:278-92. [CrossRef]
Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, et al. Ova- rian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008;108:136-40. [CrossRef]
Kunkel J, Peng Y, Tao Y, Krigman H, Cao D. Presence of a sar- comatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mul- lerian tumors: a clinicopathologic study of 47 cases. Am J Surg Pathol 2012;36:831-7. [CrossRef]
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18. [CrossRef]
Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol 2012;127:22-6. [CrossRef]
Tanner EJ, Leitao MM Jr, Garg K, Chi DS, Sonoda Y, Gard- ner GJ, et al. The role of cytoreductive surgery for newly diag- nosed advanced-stage uterine carcinosarcoma. Gynecol Oncol 2011;123:548-52. [CrossRef]
Doo DW, Erickson BK, Arend RC, Conner MG, Huh WK, Leath CA 3rd. Radical surgical cytoreduction in the treatment of ovari- an carcinosarcoma. Gynecol Oncol 2014;133:234-7. [CrossRef]